Maarten van den Berg

Cardiologist

Maarten van den Berg is full professor of cardiology at the University of Groningen. Since 1992 he worked as a cardiologist in the University Medical Center Groningen, first in general cardiology and as director of the residency program cardiology. Later he focused on cardiogenetics. He was one of the founders of cardiogenetics in the Netherlands and he has a broad experience in related patient care and research.  He is interested in cardiomyopathies, including non-hereditary forms, e.g. amyloidosis.  Gene-environment interactions and genotype-phenotype relations are among his research topics. He is also an expert in connective tissues diseases, including Marfan’s syndrome.

My projects

iPHORECAST

PHOspholamban RElated CArdiomyopathy STudy

Transthyretin amyloidosis cardiomyopathy

PLN cardiomyopathy

Investigating and treating phospholamban cardiomyopathy

My publications

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy

Tim R Eijgenraam, Bastiaan J Boukens, Cornelis J Boogerd, Marloes Schouten, Cees W A van de Kolk, Nienke M Stege, Wouter P Te Rijdt, Edgar T Hoorntje, Paul A van der Zwaag, Eva van Rooij, J Peter van Tintelen, Maarten P van den Berg, Peter van der Meer, Jolanda van der Velden, Herman H W Silljé, Rudolf A de Boer. Sci Rep. 2020

view on PubMed

Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.

The objective of this study was to assess the association of digoxin with cardiovascular (CV) morbidity and mortality in patients with permanent atrial fibrillation enrolled in the Dutch Rate Control Efficacy in Permanent AF: A Comparison Between Lenient Versus Strict Rate Control II trial as well as to assess the role of digoxin to achieve heart rate targets. The use of digoxin was not associated with increased morbidity and mortality.

view on Heart Rhythm Journal

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.

Heart failure with preserved ejection fraction and AF are very common diseases that also often occur in combination, further aggravating each other. Senile amyloidosis, either due to TTR (ATTRwt) or ANP (IAA) appears to play an important role in both diseases and in their interaction. In terms of diagnostics, bone scintigraphy has become available and affords an easy and reliable way to establish the presence of cardiac ATTRwt. Moreover, pharmacological options are now available or under development to treat ATTRwt and possibly also IAA, thereby potentially stopping, or even reversing, the downhill course of some patients with HFpEF and AF.

view on Oxford Academic

Heart failure with preserved ejection fraction, atrial fibrillation, and role of senile amyloidosis.

van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, van Veldhuisen DJ, van der Meer P, Nienhuis HLA, Hazenberg BPC, Rienstra M. Eur Heart J 2019

view on publisher site

A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy.

Rivaud MR, Jansen JA, Postema PG, Mizusawa Y, van der Nagel R, Wolswinkel R, van der Made I, Marchal G, Rajamani S, Belardinelli L, van Tintelen JP, Tanck MWT, van der Wal A, de Bakker JMT, van Rijen HV, Creemers EE, Wilde AAM, van den Berg MP, van Veen TAB, Bezzina CR,‬‬ Remme CA. Eur Heart J 2018

view on publisher site